| News
i4Challenge in its 3rd year is now accpeting applications
05.06.2020
The i4Challenge is an acceleration program for SME, startups and new projects focused on innovative solutions, new approaches and next-generation products or services for Industry 4.0.
Have you, or anyone you know developed innovative solutions, novel approaches and sophisticated products in the field of Industry 4.0? Then we would suggest you apply for the i4Challenge, accepting applications now. Learn more at www.i4Challenge.com.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Switzerland Innovation Park Basel Area Site Novartis Campus
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.
Read More
The innovation and enterprise campus GRID is filling up
Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation and enterprise campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.
Read More
Artidis ends successful study
Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.
Read More
Startup Academy celebrates anniversary
Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.
Read More
Syngenta grows strongly and stays true to Basel
Syngenta AG, Adama and Sinochem are to be united under the umbrella of the new Syngenta Group. The group is headquartered in Basel and employs around 48,000 staff across over 100 countries.
Read More
Tolremo raises additional funding
The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.
Read More
